GD2 is expressed at low levels on some peripheral nerves and anti-GD2 antibody therapy can result in a transient pain syndrome; therefore in order to anticipate and prevent on-target, off-tumour toxicity directed against peripheral nerve GD2 we have incorporated the well-characterised inducible caspase 9 (iCasp9) suicide gene into our CAR cassette [11]. The gene discussed is CASP9; the disease is neoplasm.